[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619669":3},{"organization":4,"outcomesModule":7,"designInfo":49,"detailedDescription":57,"studyPopulation":48,"armGroups":58,"interventions":71,"overallOfficials":79,"centralContacts":90,"locations":100,"responsibleParty":184,"collaborators":186,"id":190,"slug":48,"hasResults":191,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":191,"sex":197,"minAge":198,"maxAge":48,"enrollmentInfo":199,"targetDuration":48,"studyType":202,"phases":203,"briefSummary":205,"conditions":206,"keywords":208,"overallStatus":212,"whyStopped":48,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":222},{"fullName":5,"class":6},"Xinqiao Hospital of Chongqing","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":48},[9],{"measure":10,"description":11,"timeFrame":12},"Excellent functional outcome","modified Rankin scale score of 0 to 1. modified Rankin scale scores range from 0 to 6, with 0 indicating no disability, 1 no clinically significant disability, 2 slight disability, 3 moderate disability but able to walk unassisted, 4 moderately severe disability, 5 severe disability, and 6 death.","90 days post-randomization",[14,17,21,24,28,32,35,38,41,44],{"measure":15,"description":16,"timeFrame":12},"Ordinal degree of disability","Ordinal degree of disability on the modified Rankin scale score at 90 days (shift analysis)",{"measure":18,"description":19,"timeFrame":20},"Conversion to Endovascular Therapy","Proportion of patients who converted to endovascular therapy","24 hours post-randomization",{"measure":22,"description":23,"timeFrame":12},"Functionally independent","modified Rankin scale score of 0 to 2",{"measure":25,"description":26,"timeFrame":27},"Change in NIHSS Score at 48 (±12) Hours","Change in NIHSS score from pre-randomization to 48 (±12) hours","48 (±12) hours post-randomization",{"measure":29,"description":30,"timeFrame":31},"Change in NIHSS Score at Discharge or Day 6 (±1)","Change in NIHSS score from pre-randomization to discharge or day 6 (±1)","Day 6 (±1) or discharge post-randomization, whichever came first",{"measure":33,"description":34,"timeFrame":12},"Health-related quality of life","assessed with the European Quality Five Dimensions Five Level scale",{"measure":36,"description":37,"timeFrame":27},"Symptomatic intracranial hemorrhage","defined as per the Heidelberg bleeding classification",{"measure":39,"description":40,"timeFrame":12},"Mortality","The proportion of participants who die from any cause within 90 days after randomization in the study",{"measure":42,"description":43,"timeFrame":27},"Incidence of major extracranial bleeding within 48 (±12) hours","GUSTO criteria: moderate and severe bleeding",{"measure":45,"description":46,"timeFrame":47},"Incidence of non-hemorrhagic serious adverse events","Including but not limited to cerebral herniation, pneumonia, respiratory failure, circulatory failure, stress ulcer, secondary epilepsy, urinary tract infection, sepsis, renal failure, acute coronary syndrome, venous thrombosis, and psychiatric symptoms","Within 90 days post-randomization",null,{"allocation":50,"interventionModel":51,"interventionModelDescription":48,"primaryPurpose":52,"observationalModel":48,"timePerspective":48,"maskingInfo":53},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":54,"maskingDescription":48,"whoMasked":55},"SINGLE",[56],"OUTCOMES_ASSESSOR","Several clinical trials (e.g., TRACE-3, EXPECTS, HOPE) have successfully extended the time window for intravenous thrombolysis (IVT) from the conventional 4.5 hours up to 24 hours after symptom onset by utilizing advanced imaging selection techniques. Consequently, the 2024 Chinese guidelines for reperfusion therapy recommend IVT for patients presenting 4.5 to 24 hours after onset, based on imaging selection criteria. However, clinical practice indicates that a considerable proportion of patients exhibit suboptimal recanalization outcomes or even experience early neurological deterioration (END) despite receiving standard IVT. Previous research, such as the ASSET-IT trial, has primarily focused on patients treated within 4.5 hours of onset. For the growing population of \"extended-window\" (4.5-24 hours) patients receiving IVT facilitated by advances in imaging, the optimal antiplatelet strategy following thrombolysis remains an area with no high-level evidence. Therefore, this study aims to evaluate the efficacy and safety of early administration of eptifibatide following standard IVT (with tenecteplase or alteplase) in patients with acute ischemic stroke who present 4.5 to 24 hours after symptom onset. Patients who have received standard IVT but exhibit early neurological deterioration, fluctuation, or lack of significant improvement within 1 hour post-thrombolysis will be randomized 1:1 to receive either eptifibatide (a single intravenous bolus followed by a 2-hour infusion) plus standard medical therapy or standard medical therapy alone. The primary efficacy outcome is the proportion of patients achieving an excellent functional outcome (modified Rankin Scale score of 0-1) at 90 days. The primary safety outcome is the incidence of symptomatic intracranial hemorrhage within 48 hours after randomization. A total of 786 participants are planned to be enrolled to detect a 10% absolute difference in the primary outcome with 80% power.",[59,65],{"label":60,"type":61,"description":62,"interventionNames":63},"Eptifibatide (Integrilin)","EXPERIMENTAL","Participants randomized to this arm will receive intravenous eptifibatide (135 μg\u002Fkg bolus, followed by 0.75 μg\u002Fkg\u002Fmin infusion for 2 hours) initiated within 60 minutes after completion of standard intravenous thrombolysis (either alteplase or tenecteplase). Antiplatelet therapy with aspirin (100 mg) and\u002For clopidogrel (75 mg) will be administered at 24h after thrombolysis until the follow-up period of 90 days.",[64],"Drug: Eptifibatide (Integrilin)",{"label":66,"type":67,"description":68,"interventionNames":69},"Standard Medical Therapy","ACTIVE_COMPARATOR","Participants randomized to this arm will not receive intravenous eptifibatide after completion of standard intravenous thrombolysis. Antiplatelet therapy with aspirin (100 mg) and\u002For clopidogrel (75 mg) will be administered at 24h after thrombolysis until the follow-up period of 90 days.",[70],"Drug: Standard Medical Therapy",[72,76],{"type":73,"name":60,"description":74,"armGroupLabels":75,"otherNames":48},"DRUG","Participants will receive intravenous eptifibatide (135 μg\u002Fkg bolus, followed by 0.75 μg\u002Fkg\u002Fmin infusion for 2 hours) initiated within 60 minutes after completion of standard intravenous thrombolysis (either alteplase or tenecteplase). Antiplatelet therapy with aspirin (100 mg) and\u002For clopidogrel (75 mg) will be administered at 24h after thrombolysis until the follow-up period of 90 days.",[60],{"type":73,"name":66,"description":77,"armGroupLabels":78,"otherNames":48},"Participants will not receive intravenous eptifibatide after completion of standard intravenous thrombolysis. Antiplatelet therapy with aspirin (100 mg) and\u002For clopidogrel (75 mg) will be administered at 24h after thrombolysis until the follow-up period of 90 days.",[66],[80,84,87],{"name":81,"affiliation":82,"role":83},"Zhongming Qiu, MD","Xinqiao Hospital of the Army Medical University","PRINCIPAL_INVESTIGATOR",{"name":85,"affiliation":86,"role":83},"Zhenqiang Zhao, MD","The First Affiliated Hospital of Hainan Medical University",{"name":88,"affiliation":89,"role":83},"Daojun Hong, MD","The First Affiliated Hospital of Nanchang University",[91,96],{"name":92,"role":93,"phone":94,"phoneExt":48,"email":95},"Wei Li, MD","CONTACT","+86 18976574937","weiligysy@163.com",{"name":97,"role":93,"phone":98,"phoneExt":48,"email":99},"Jing Lin, MD","+86 15626456674","linjingsys2016@126.com",[101,119,133,148,158,172],{"facility":102,"status":48,"city":103,"state":104,"zip":105,"country":106,"countryCode":107,"cosmosGeoPoint":108,"geoPoint":113,"contacts":114},"Xinqiao Hospital and The Second Affiliated Hospital","Chongqing","Chongqing Municipality","400000","China","CN",{"type":109,"coordinates":110},"Point",[111,112],106.55771,29.56026,{"lat":112,"lon":111},[115],{"name":116,"role":93,"phone":117,"phoneExt":48,"email":118},"Zhongming Qiu","+86 13236599269","qiuzhongmingdoctor@163.com",{"facility":86,"status":48,"city":120,"state":121,"zip":122,"country":106,"countryCode":107,"cosmosGeoPoint":123,"geoPoint":127,"contacts":128},"Haikou","Hainan","570100",{"type":109,"coordinates":124},[125,126],110.34651,20.03421,{"lat":126,"lon":125},[129],{"name":130,"role":93,"phone":131,"phoneExt":48,"email":132},"Zhenqiang Zhao","+86 13976015677","zhenqiang.zhao@qq.com",{"facility":134,"status":48,"city":135,"state":136,"zip":137,"country":106,"countryCode":107,"cosmosGeoPoint":138,"geoPoint":142,"contacts":143},"Ganzhou People's Hospital","Ganzhou","Jiangxi","341000",{"type":109,"coordinates":139},[140,141],114.9326,25.84664,{"lat":141,"lon":140},[144],{"name":145,"role":93,"phone":146,"phoneExt":48,"email":147},"Guoyong Zeng","+86 13507079530","hsyygy@163.com",{"facility":149,"status":48,"city":135,"state":136,"zip":137,"country":106,"countryCode":107,"cosmosGeoPoint":150,"geoPoint":152,"contacts":153},"The First Affiliated Hospital of Gannan Medical University",{"type":109,"coordinates":151},[140,141],{"lat":141,"lon":140},[154],{"name":155,"role":93,"phone":156,"phoneExt":48,"email":157},"Qiujiang Xi","+86 18170868978","Xiqiujiang992437@sina.com",{"facility":159,"status":48,"city":160,"state":136,"zip":161,"country":106,"countryCode":107,"cosmosGeoPoint":162,"geoPoint":166,"contacts":167},"The Affiliated Hospital of Jinggangshan University","Ji’an","343000",{"type":109,"coordinates":163},[164,165],114.97927,27.11716,{"lat":165,"lon":164},[168],{"name":169,"role":93,"phone":170,"phoneExt":48,"email":171},"Yongcheng Zhang","+86 13970656839","2378666511@qq.com",{"facility":89,"status":48,"city":173,"state":136,"zip":174,"country":106,"countryCode":107,"cosmosGeoPoint":175,"geoPoint":179,"contacts":180},"Nanchang","330006",{"type":109,"coordinates":176},[177,178],115.85306,28.68396,{"lat":178,"lon":177},[181],{"name":88,"role":93,"phone":182,"phoneExt":48,"email":183},"+86 13879187691","hongdaojun@hotmail.com",{"type":83,"investigatorFullName":116,"investigatorTitle":185,"investigatorAffiliation":5,"oldNameTitle":48,"oldOrganization":48},"Professor",[187,189],{"name":86,"class":188},"OTHER_GOV",{"name":89,"class":6},"100619669",false,"NCT07347626","Eptifibatide for Extended Window Ischemic Stroke After Thrombolysis","Efficacy and Safety of Eptifibatide Therapy Following Intravenous Thrombolysis in Acute Ischemic Stroke Patients Within 4.5 to 24 Hours After Onset: A Multicenter, Randomized Controlled Trial","E-TWIST","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Acute ischemic stroke, with the time interval from last known well to hospital presentation being 4.5 to 24 hours.\n3. NIHSS score ≥ 4 before randomization; if large or medium vessel occlusion is present, an NIHSS score ≤ 10 is also required.\n4. Presence of any of the following conditions after completion of standard intravenous thrombolysis:\n\n   1. No significant neurological improvement within 1 hour (defined as a change in NIHSS score ≤ 1 point from baseline).\n   2. Early neurological deterioration within 1 hour of onset (defined as an increase in NIHSS score ≥ 2 points from baseline).\n   3. Neurological fluctuation within 24 hours after symptom onset (defined as an increase in NIHSS score ≥ 2 points from the lowest value post-thrombolysis).\n5. Ability to receive the assigned study drug within 60 minutes after intravenous thrombolysis.\n6. Signed written informed consent obtained from the patient or their legal representative.\n\nExclusion Criteria:\n\n1. Intracranial hemorrhage confirmed by CT or MRI.\n2. Planned endovascular therapy.\n3. Presence of any definite cardioembolic source, including: chronic or paroxysmal atrial fibrillation, sick sinus syndrome, mitral stenosis, mechanical heart valve, endocarditis, intracardiac thrombus or vegetation, myocardial infarction within 3 months, dilated cardiomyopathy, spontaneous echo contrast in the left atrium, or ejection fraction \\\u003C 30%.\n4. Pre-stroke modified Rankin Scale (mRS) score ≥ 2.\n5. Renal insufficiency (glomerular filtration rate \\\u003C 30 ml\u002Fmin or serum creatinine \\> 220 μmol\u002FL \\[2.5 mg\u002FdL\\]).\n6. Known hypercoagulable state.\n7. Platelet count \\\u003C 100 × 10⁹\u002FL.\n8. Pregnancy or lactation.\n9. Allergy to eptifibatide, other glycoprotein IIb\u002FIIIa inhibitors, aspirin, or clopidogrel.\n10. History of non-atherosclerotic arteriopathy, including moyamoya disease, arterial dissection, or fibromuscular dysplasia.\n11. Pre-existing neurological or psychiatric disease that would preclude accurate neurological assessment.\n12. History of bleeding diathesis, severe cardiac disease, liver disease, or sepsis.\n13. Brain tumor with mass effect on imaging (except for small meningiomas).\n14. Evidence of intracranial arteriovenous malformation or aneurysm with diameter \\> 5 mm on CT or MR angiography.\n15. Current participation in another clinical trial.\n16. Any terminal illness with life expectancy \\\u003C 6 months.\n17. Anticipated inability to complete follow-up.","ALL","18 Years",{"count":200,"type":201},786,"ESTIMATED","INTERVENTIONAL",[204],"PHASE3","This is a multicenter, randomized, open-label, blinded-endpoint clinical trial designed to evaluate the efficacy and safety of early administration of eptifibatide following intravenous thrombolysis in patients with acute ischemic stroke who present 4.5 to 24 hours after symptom onset.",[207],"Acute Ischemic Stroke",[207,209,210,211],"Intravenous thrombolysis","Eptifibatide","Neurological deterioration","NOT_YET_RECRUITING","2026-01-15",{"date":215,"type":216},"2026-01-16","ACTUAL",{"date":218,"type":201},"2026-03-01",{"date":220,"type":201},"2029-12-31",{"name":5,"class":6},6]